ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
15.2 ^USD	-2.19%		+0.66%	-51.45%

May. 16	Transcript : ACADIA Pharmaceuticals Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM
May. 10	UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating	MT

Acadia Pharmaceuticals Inc. Reiterates Earnings Guidance for the Full Year 2024

May 08, 2024 at 04:05 pm EDT

ACADIA Pharmaceuticals Inc. reiterated earnings guidance for the full year 2024. For the year, the company expects DAYBUE net product sales guidance in the range of $370 million to $420 million. NUPLAZID net product sales guidance in the range of $560 million to $590 million.

Latest news about ACADIA Pharmaceuticals Inc.

Transcript : ACADIA Pharmaceuticals Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM	May. 16
UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating	May. 10	MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating	May. 10	MT
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million	May. 09	MT
Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating	May. 09	MT
Transcript : ACADIA Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q1 Revenue $205.8M, vs. Street Est of $208.6M	May. 08	MT
Acadia Pharmaceuticals Inc. Reiterates Earnings Guidance for the Full Year 2024	May. 08	CI
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating	Apr. 30	MT
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	Apr. 22	MT
Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	Apr. 22	MT
Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada	Apr. 22	CI
ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting	Apr. 17	CI
ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development	Apr. 02	CI
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing	Mar. 28	MT
JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating	Mar. 25	MT
Transcript : ACADIA Pharmaceuticals Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 02:00 PM	Mar. 18
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating	Mar. 13	MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept	Mar. 13	MT
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating	Mar. 12	MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating	Mar. 12	MT
Sector Update: Health Care Stocks Gain Premarket Tuesday	Mar. 12	MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating	Mar. 12	MT

Chart ACADIA Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ACADIA Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.2 USD

Average target price

27.16 USD

Spread / Average Target

+78.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACADIA PHARMACEUTICALS INC.	-51.45%	2.51B
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+44.98%	40.65B
CELLTRION, INC.	-10.87%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research